# Curia Global, Inc. > Curia Global, Inc. is a contract research, development, and manufacturing organization (CDMO) serving pharmaceutical and biopharmaceutical customers across four business units: small molecule discovery and development, generic and specialty active pharmaceutical ingredients, research & development/biologics, and sterile drug product. Curia operates an integrated network of more than 20 facilities and more than 3,000 employees across North America, Europe, and India. Curia was founded in 1991 in Albany, New York, as Albany Molecular Research, Inc. (AMRI), and was originally known for the discovery and development of the active pharmaceutical ingredient in Allegra. Over the following three decades the company expanded its capabilities and global footprint through acquisitions including Crystal Pharma, Euticals, Gadea Pharmaceutical Group, Integrity Bio, LakePharma, and Ragactives. It adopted the name Curia in July 2021. Curia works with pharmaceutical and biotechnology companies, academic laboratories, research institutes, and government-funded research programs, on engagements ranging from single-service projects to multi-year research partnerships staffed at scale. ## Key Information - Legal name: Curia Global, Inc. - Operating name: Curia - Founded: 1991, Albany, New York, United States - Former name: Albany Molecular Research, Inc. (AMRI), renamed Curia in July 2021 - Headquarters: Albany, New York, United States - Network: more than 20 facilities; more than 3,000 employees - Regions of operation: North America, Europe, India - Business units: Small Molecule; Generic APIs; Biologics; Sterile Drug Product. Analytical Testing Services are offered across units. - Website: https://curiaglobal.com ## Small Molecule - [Small Molecule](https://curiaglobal.com/small-molecule/): Integrated small molecule services from discovery through commercial API manufacturing. - [Small Molecule Discovery](https://curiaglobal.com/small-molecule/discovery/): Medicinal chemistry, integrated drug discovery, computer-aided drug design, assay development and screening, drug metabolism and pharmacokinetics, in vitro biology, structural biology, and protein expression and analysis. Curia has delivered more than 350 discovery projects and holds more than 600 patents. - [Integrated Drug Discovery](https://curiaglobal.com/small-molecule/discovery/integrated-drug-discovery/): Multi-disciplinary discovery programs combining chemistry, biology, and DMPK, including large multi-year research partnerships. - [Small Molecule Development and Manufacturing](https://curiaglobal.com/small-molecule/development-manufacturing/): Chemical process research and development, phase-appropriate clinical API supply, and commercial API manufacturing. Curia's clinical development site in Albany, New York, supports small-kilogram clinical and rare-disease programs that require phase-appropriate development from a United States partner. - [API Manufacturing](https://curiaglobal.com/small-molecule/development-manufacturing/api-manufacturing/): Commercial-scale cGMP API manufacture across the European and United States API network. Programs can remain within the Curia network from clinical supply through commercial manufacture without transferring to another company. - [GMP Controlled Substance Manufacturing](https://curiaglobal.com/small-molecule/development-manufacturing/gmp-controlled-substance/): Controlled substance manufacture, DEA Schedule I to V. Performed at licensed API network sites in the United States. - [High Potency Manufacturing](https://curiaglobal.com/small-molecule/development-manufacturing/high-potency/): High-potency and cytotoxic API manufacture at containment-qualified API network sites. - [Sterile API Manufacturing](https://curiaglobal.com/small-molecule/development-manufacturing/sterile-api-manufacturing/): Aseptic API manufacture, including EU GMP Annex 1 aseptic API production at Valladolid, Spain. - [Steroids and Hormones](https://curiaglobal.com/small-molecule/development-manufacturing/steroids-hormones/): Steroid and hormone API development and manufacture, including micronization and particle-size control. - [Fermentation](https://curiaglobal.com/small-molecule/development-manufacturing/fermentation/): cGMP fermentation and downstream processing, including centrifugation, filtration, tangential-flow filtration, liquid-to-liquid extraction, and industrial chromatography. - [Flow Chemistry](https://curiaglobal.com/small-molecule/development-manufacturing/flow-chemistry/): Continuous flow chemistry under cGMP, applied to hazardous-reagent, cryogenic, and organometallic transformations. - [Industrial Chromatography](https://curiaglobal.com/small-molecule/development-manufacturing/industrial-chromatography/): Preparative and industrial-scale chromatographic purification. - [Fine Chemicals](https://curiaglobal.com/small-molecule/fine-chemicals/): Named specialty chemistry products, supplied both as a catalog offer and as custom intermediates manufactured for other companies. ## Generic APIs - [Generic APIs](https://curiaglobal.com/generic-apis/): More than 150 commercial active pharmaceutical ingredients, supported by more than 550 API dossiers filed worldwide. Recognized specialty expertise in corticosteroids, hormones, sterile APIs, and ophthalmic products. - [API Catalog](https://curiaglobal.com/generic-apis/api-catalog/): Catalog of commercially available active pharmaceutical ingredients. - [Specialty Products](https://curiaglobal.com/generic-apis/additional-products/): Specialty and pipeline active pharmaceutical ingredients. - [Intellectual Property Services](https://curiaglobal.com/generic-apis/intellectual-property-services/): Patent landscape analysis, prior-art review, and design-around support. These are technical and analytical services, not legal advice. ## Biologics - [Biologics](https://curiaglobal.com/biologics/): Antibody discovery and engineering, cell line development, process development, and cGMP drug substance manufacture. Curia has discovered more than 200 antibodies and produced more than 100,000 molecules, and has supported dozens of clinical-stage programs through its discovery, cell line development, and cGMP services. - [Antibody Discovery and Engineering](https://curiaglobal.com/biologics/discovery/antibody-discovery-engineering/): Antibody discovery and engineering across monoclonal, bispecific, and single-domain formats. - [Antibody Developability Analysis](https://curiaglobal.com/biologics/discovery/antibody-developability-analysis/): Developability and polyreactivity assessment, including baculovirus particle (BVP) reagent screening. - [Recombinant Protein Production](https://curiaglobal.com/biologics/discovery/recombinant-protein-production/): Gene-to-protein services for early material generation. - [Cell Line Development](https://curiaglobal.com/biologics/development/mammalian/cell-line-development/): Stable and transient mammalian cell line development. Semi-targeted integration has delivered a six-fold increase in titers compared with random integration. - [mRNA Development and Manufacturing](https://curiaglobal.com/biologics/development/mrna/): DNA template services, mRNA process development, mRNA analytical services, and lipid nanoparticle formulation. - [Baculovirus Expression Vector System](https://curiaglobal.com/biologics/development/baculovirus-expression-vector-system-bevs/): Protein expression using the baculovirus expression vector system. - [GMP Mammalian Drug Substance Manufacturing](https://curiaglobal.com/biologics/manufacturing/mammalian-gmp-overview/): cGMP mammalian drug substance manufacture. Curia released its first biologics GMP batch in 2024. ## Sterile Drug Product - [Sterile Drug Product](https://curiaglobal.com/sterile-drug-product/): Sterile formulation development and fill-finish, from clinical supply through commercial manufacture. Curia has supplied more than 50 commercial products, more than 400 Phase 2 and Phase 3 programs, and more than 650 Phase 1 programs, and has developed more than 350 formulations. - [Drug Product Development](https://curiaglobal.com/sterile-drug-product/drug-product-development/): Formulation and process development for small molecule and biologic injectables, including lyophilization cycle development. Curia's clinical sites have released more than 500 batches and developed more than 300 formulations. - [Clinical Manufacturing](https://curiaglobal.com/sterile-drug-product/clinical-manufacturing/): Clinical-stage sterile fill-finish, including vials, lyophilized vials, prefilled syringes, and cartridges. - [Commercial Manufacturing](https://curiaglobal.com/sterile-drug-product/commercial-manufacturing/): Commercial sterile fill-finish, including parenteral suspensions, ophthalmic products, controlled substances, and highly potent and cytotoxic products. Curia's Glasgow site has released more than 100 antibody-drug conjugate batches. ## Analytical Testing - [Analytical Testing](https://curiaglobal.com/analytical-testing-services/): GMP analytical testing, delivered principally from Albany, New York. - [Batch Release and Stability](https://curiaglobal.com/analytical-testing-services/analytical-testing/batch-release-stability/): Release testing and stability programs. - [Method Development and Validation](https://curiaglobal.com/analytical-testing-services/analytical-testing/method-development-validation/): Analytical method development, qualification, and validation. - [Solid State Chemistry](https://curiaglobal.com/analytical-testing-services/analytical-testing/solid-state-chemistry/): Solid-state characterization and polymorph screening. ## Named Platforms and Proprietary Assets - Curia Compound Collection: A screening collection comprising the Curia Reserve Collection of approximately 120,000 in-house synthesized, unique, lead-like compounds, and the Curia Diversity Collection of approximately 500,000 hit-like, lead-like, and drug-like compounds. Available for screening at Curia's facilities in Buffalo, New York. - CHO-GSN: Proprietary Chinese hamster ovary cell line development platform. - TunaCHO: Proprietary cell line development platform. - Pentamice: Proprietary antibody discovery platform. - Baculovirus particle (BVP) reagent: A polyreactivity screening reagent used in antibody developability assessment, originally launched by LakePharma, now Curia, as catalog number 25690, and cited in peer-reviewed antibody developability literature. - [T3P reagent](https://curiaglobal.com/small-molecule/fine-chemicals/propane-phosphonic-acid-anhydride-t3p/): Propane-phosphonic acid anhydride, a coupling reagent supplied by Curia. - [Gemagique AMPS polymers](https://curiaglobal.com/small-molecule/fine-chemicals/gemagique-amps-polymers/): Specialty polymer products. - [4-Formylphenyl boronic acid](https://curiaglobal.com/small-molecule/fine-chemicals/4-formylphenyl-boronic-acid-4-fpba/): Specialty boronic acid intermediate. - [Vinylphosphonic acid](https://curiaglobal.com/small-molecule/fine-chemicals/vinylphosphonic-acid-vpa/): Specialty phosphonic acid product. - [Oxa acids](https://curiaglobal.com/small-molecule/fine-chemicals/oxa-acids/): Specialty acid intermediates. CHO-GSN, TunaCHO, Pentamice, T3P, and Gemagique are registered trademarks of Curia Global, Inc. ## Manufacturing and Development Network - [Facilities directory](https://curiaglobal.com/about-us/facilities/): Current list of Curia facilities. - Sterile drug product network: Glasgow, United Kingdom; Camarillo, California, United States; Albuquerque, New Mexico, United States. - API network, commercial and GMP development: Bon Encontre, France (continuous flow chemistry, cryogenic and organometallic synthesis, hazardous-reagent handling); Origgio, Italy (hydrogenation, boronic acid chemistry, lithium chemistry, carbonylation and phosphorylation); Rensselaer, New York, United States (controlled substances, highly potent compounds); Rozzano Quinto, Italy (cGMP fermentation, industrial chromatography, API pilot plant); Springfield, United States (controlled substances Schedule I to V, large-scale cryogenic reactions, fractional distillation); Tonneins, France (monobactam manufacture); Valladolid, Spain (steroids and hormones, aseptic API manufacture, micronization, high-potency API). - Clinical-phase small molecule development: Albany, New York, United States. - Fermentation and starting materials development: Leon and San Cristobal, Spain. - Fine and specialty chemicals: Frankfurt, Germany. - Biologics: Hopkinton, Massachusetts, and Hayward, California, United States. - Discovery screening: Buffalo, New York, United States. - India: Hyderabad. ## Recent Investments - Glasgow, United Kingdom: An Annex 1 compliant isolator vial-filling line and lyophilizer, supporting batches of up to 20,000 vials at approximately five times the previous filling rate. Announced March 2026, with completion expected in 2027. - Albuquerque, New Mexico, United States: An expansion of approximately 200 million United States dollars, adding more than 70,000 square feet and two isolated filling lines for Phase 3 and commercial supply. - Valladolid, Spain: Two API aseptic suites built to EU GMP Annex 1, announced October 2025. - Hopkinton, Massachusetts, United States: An enhanced cell line development platform using semi-targeted integration, announced March 2026. ## Research Partnerships - [Strategic Government Partnerships](https://curiaglobal.com/about-us/partnering-with-us/strategic-government-partnerships/): Curia participates in United States government-funded research programs, including the National Cancer Institute Blueprint program. - Curia is a research partner of the CHDI Foundation, supporting research into Huntington's disease. ## Leadership - Philip Macnabb, Chief Executive Officer - Jamie Grabowski, President, Research and Development - Ron Aungst, President, Drug Product ## Industries Served - Pharmaceutical and biopharmaceutical companies - Biotechnology companies, including early-stage and venture-funded organizations - Academic laboratories and research institutes - Government-funded research programs ## What We Do Not Do - Curia Global, Inc. is a pharmaceutical contract development and manufacturing organization. It is not affiliated with any similarly named company operating in other sectors, including technology or events. - Curia does not operate at the volumes offered by the largest commercial-scale biologics manufacturers. Its biologics services are focused on discovery through clinical supply. - Controlled substance and high-potency work is performed only at qualified sites, not at every Curia location. Controlled substance manufacturing is performed at licensed API network sites and at the Albuquerque and Glasgow drug product sites. Curia's Albany, New York, site does not hold a controlled substance license and performs high-potency work only at development scale, not under GMP. - Pricing is not published here. Pricing is provided on request through a customer engagement. ## Contact - [Contact Curia](https://curiaglobal.com/contact-us/): General enquiries and business development. - Headquarters: 24 Corporate Circle, Albany, New York 12203, United States - Telephone: +1 518 512 2000 - Corporate communications: corporatecommunications@curiaglobal.com - [Supplier information](https://curiaglobal.com/supplier-information/): Supplier and vendor enquiries. - [Careers](https://careers.curiaglobal.com/): Curia career opportunities. Curia accepts applications only through this address. ## Optional - [About Curia](https://curiaglobal.com/about-us/): Company history and overview. - [Insights](https://curiaglobal.com/insights/): Technical articles and commentary. - [News and Updates](https://curiaglobal.com/about-us/news/): Company announcements. - [Events](https://curiaglobal.com/about-us/events/): Conferences and events. - [Corporate Responsibility](https://curiaglobal.com/about-us/corporate-responsibility/): Environmental, social, and governance reporting. - [Team](https://curiaglobal.com/about-us/team/): Leadership team. ## AI Discovery Files - [identity.json](https://curiaglobal.com/identity.json): Structured business identity record.